Gerd Altmann/pixabay.com

Life science associations are calling for ATMPs to be exempted from the strict EU GMO rules, as their different legal interpretations in EU member states are delaying applications for multicentre clinical trials.

© APEIRON Biologics

APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds.

© Hummingbird Bioscience

Danish Novo Holdings A/S has led an oversubscribed US$125m Series C into the cancer antibody specialist Hummingbird Bioscience.

Animation of BD's Zaragoza plant. © BD

BD will build a €165m manufacturing facility in Zaragoza, Spain to support the growth of its pre-filled drug delivery business.

REGN10933 (blue) and REGN10987 (orange) bound to SARS-CoV-2 spike protein (pink). REGN-CoV got an FDA-EUA on 23 November 2020. © Fvasconcellos/wikipedia

German government has launched a €300m programme designed to bring clinically tested COVID-19 treatments to the patient’s bedside.

Amsilk's E.coli-made Biosteel fibre is being developed in partnerships to develop running ultra-lightweigt running shoes and composites with high mechanical robustness for use in the aerospace industry. © AMSilk GmbH

AMSilk GmbH has closed a Series C financing at €29m to accelerate and expand commercialisation of its microbially produced silk fibres.

Thanks to a grant by Germany's €45m funding programme for clinical COVID-19 therapeutics set up in January 2021, CORAT Therapeutics got money to start their Phase I/II programme with COR-101. In May the funding programme will be upgraded by €300m - a model for the EU? © NIAID

Immunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.

© Pixabay.com

International life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.

© UNICEF

The Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.

© Oculis SA

Topical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.